ArticleBiomaterials research2026
Focused Ultrasound-Triggered Burst Release and Enrichment of Engineered Bacteria for Tumor Therapy.
Article in Biomaterials research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ultrasound has been widely used in bacteria-based tumor therapy for targeted drug delivery due to its noninvasive ability to control bacteria. However, current approaches achieve only gradual release of therapeutic agents and rely on limited natural homing ability, resulting in poor treatment efficacy. Here, we demonstrate that focused ultrasound (FUS) can simultaneously induce burst release within tumors and local enrichment of therapeutics, enhancing precise and controllable spatiotemporal drug delivery efficiency within tumor microenvironments in living-therapeutic biomaterial system. We achieved FUS-triggered bacterial burst release by coexpressing gas vesicles (GVs), protein nanostructures that induce cavitation, and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), which increases antitumor efficacy. Furthermore, we show that FUS enhances enrichment of therapeutics at the tumor site by manipulating bacteria toward tumor vessel walls and increasing tumor permeability via sonopermeation. In a mouse model, we demonstrated clinical potential by achieving a 40% reduction in tumor volume using probiotic
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.